In addition, the potential core targets of FZD in the treatment of osteoporosis were selected using CytoNCA, which included IFNG, HMOX1, CAT, AKT1, PTGS2, ESR1, PPARG, CASP3, IL1B, CYP1A1, NR3C1, and VCAM1 (Fig. 3B). This evidence concerns the gene ESR1 and osteoporosis.